NVS vs TMO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Novartis exhibits a stable financial foundation with a Piotroski F-Score of 6/9, yet it faces significant valuation headwinds. The stock is trading at a massive premium compared to its Graham Number ($61.62) and Intrinsic Value ($48.86), while current growth metrics are negative across both revenue (-0.70%) and earnings (-9.30%). While profitability remains elite with an ROE of 34.93%, the combination of a bearish technical trend (0/100) and deteriorating quarterly earnings surprises suggests limited near-term upside.
TMO exhibits exceptional operational health with a Piotroski F-Score of 8/9, indicating strong financial stability and efficiency. However, the stock is currently trading at a significant premium, with a current price of $513.98 far exceeding both the Graham Number ($237.97) and the growth-based Intrinsic Value ($371.44). While analyst sentiment remains strongly bullish with a target of $647.38, this is countered by bearish insider activity and a negative technical trend. The outlook is balanced between high-quality fundamentals and a stretched valuation.
Compare Another Pair
Related Comparisons
NVS vs TMO: Head-to-Head Comparison
This page compares Novartis AG (NVS) and Thermo Fisher Scientific Inc. (TMO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.